Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 5/20 | 0.56 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | BLM | P54132 | 6/20 | 0.55 |
| ▸ | THRB | P10828 | 6/20 | 0.55 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.55 |
| ▸ | RECQL | P46063 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | TOP2A | P11388 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23880751 | 0.95 | S100A4 (0.60) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18821671 | 0.95 | S100A4 (0.60) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18786999 | 0.95 | S100A4 (0.60) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18786997 | 0.95 | S100A4 (0.60) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL31488734 | 0.95 | S100A4 (0.60) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18806514 | 0.94 | S100A4 (0.56) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18806505 | 0.94 | S100A4 (0.56) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18841374 | 0.94 | MEN1 (0.52) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18787141 | 0.90 | EBP (0.61) | S100A4PAX8HSP90AA1MEN1KMT2A | |
| SCHEMBL18806491 | 0.90 | EBP (0.61) | S100A4PAX8HSP90AA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319609-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2017-11-09 | — | — | US | disclosed |
| US-9737556-B2 | FAP-activated therapeutic agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170128476-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2017-05-11 | — | — | US | disclosed |
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128476-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | FAP, FIBP, GOT1 | S100A4 1836/4885PAX8 2272/4885HSP90AA1 310/4885 |
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, FAH | S100A4 1791/4885PAX8 2640/4885HSP90AA1 1290/4885 |
| US-20170319609-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | FAP, FIBP, GOT1 | S100A4 1836/4885PAX8 2272/4885HSP90AA1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.